Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

This study is focused on comparing two treatments for individuals with severe Hemophilia A, a condition where blood does not clot properly, leading to excessive bleeding. The study looks at low-dose Emicizumab and low-dose extended half-life Factor VIII treatment. These treatments are being compared to see which one better reduces bleeding episodes and improves quality of life. This is important as it could lead to more effective and manageable treatment options for people with severe Hemophilia A. Participants in the study will receive either low-dose Emicizumab or low-dose Factor VIII. Emicizumab is administered as an injection, while Factor VIII is typically given intravenously. Researchers will measure outcomes such as the annual bleeding rate, joint health, and overall quality of life. The study will also explore how the body processes these treatments and note any side effects. This information will help determine the most effective and safe treatment for reducing bleeding in Hemophilia A patients.